Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.660
0.00 (0.00%)
Aug 4, 2026, 7:06 AM EDT - Market open
Xenetic Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
The meeting was called to order with auditors and legal counsel present, but a quorum was not reached, preventing any business from being conducted. The board will set a new date for the adjourned meeting.
Fiscal Year 2024
-
Preclinical data show DNase I enhances the efficacy of immune checkpoint inhibitors in colorectal cancer models resistant to current therapies. These results support advancing DNase I combinations into clinical development for cancers where NETs drive resistance.